These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 1968359)
1. Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. Lincke CR; van der Bliek AM; Schuurhuis GJ; van der Velde-Koerts T; Smit JJ; Borst P Cancer Res; 1990 Mar; 50(6):1779-85. PubMed ID: 1968359 [TBL] [Abstract][Full Text] [Related]
2. Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. Schinkel AH; Roelofs EM; Borst P Cancer Res; 1991 May; 51(10):2628-35. PubMed ID: 1673638 [TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferase-pi. Fairchild CR; Moscow JA; O'Brien EE; Cowan KH Mol Pharmacol; 1990 Jun; 37(6):801-9. PubMed ID: 1972772 [TBL] [Abstract][Full Text] [Related]
4. Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line. Baas F; Jongsma AP; Broxterman HJ; Arceci RJ; Housman D; Scheffer GL; Riethorst A; van Groenigen M; Nieuwint AW; Joenje H Cancer Res; 1990 Sep; 50(17):5392-8. PubMed ID: 1974823 [TBL] [Abstract][Full Text] [Related]
5. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Slovak ML; Hoeltge GA; Dalton WS; Trent JM Cancer Res; 1988 May; 48(10):2793-7. PubMed ID: 2896069 [TBL] [Abstract][Full Text] [Related]
8. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143 [TBL] [Abstract][Full Text] [Related]
9. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Ford JM; Bruggemann EP; Pastan I; Gottesman MM; Hait WN Cancer Res; 1990 Mar; 50(6):1748-56. PubMed ID: 1968358 [TBL] [Abstract][Full Text] [Related]
10. Reversal of Vinca alkaloid resistance by anti-P-glycoprotein monoclonal antibody HYB-241 in a human tumor xenograft. Rittmann-Grauer LS; Yong MA; Sanders V; Mackensen DG Cancer Res; 1992 Apr; 52(7):1810-6. PubMed ID: 1348013 [TBL] [Abstract][Full Text] [Related]
11. Enhanced efflux of [3H]vinblastine from Chinese hamster ovary cells transfected with a full-length complementary DNA clone for the mdr1 gene. Hammond JR; Johnstone RM; Gros P Cancer Res; 1989 Jul; 49(14):3867-71. PubMed ID: 2736530 [TBL] [Abstract][Full Text] [Related]
12. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Yang JM; Goldenberg S; Gottesman MM; Hait WN Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786 [TBL] [Abstract][Full Text] [Related]
13. In vitro multidrug resistance of P388 murine leukemia selected for resistance to diaziquone. Gutierrez PL; Wilder PJ; Biswal N Cancer Commun; 1989; 1(3):181-90. PubMed ID: 2576972 [TBL] [Abstract][Full Text] [Related]
14. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides. Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384 [TBL] [Abstract][Full Text] [Related]
15. Cytogenetic alterations associated with P-glycoprotein- and non-P-glycoprotein-mediated multidrug resistance in SW-1573 human lung tumor cell lines. Nieuwint AW; Baas F; Wiegant J; Joenje H Cancer Res; 1992 Aug; 52(16):4361-71. PubMed ID: 1353703 [TBL] [Abstract][Full Text] [Related]
16. Sequential emergence of distinct resistance phenotypes in murine erythroleukemia cells under adriamycin selection: decreased anthracycline uptake precedes increased P-glycoprotein expression. Slapak CA; Daniel JC; Levy SB Cancer Res; 1990 Dec; 50(24):7895-901. PubMed ID: 1979251 [TBL] [Abstract][Full Text] [Related]
17. Characterization of B16 melanoma cells resistant to the CC-1065 analogue U-71,184. Moy BC; Petzold GL; Badiner GJ; Kelly RC; Aristoff PA; Adams EG; Li LH; Bhuyan BK Cancer Res; 1990 Apr; 50(8):2485-92. PubMed ID: 2317831 [TBL] [Abstract][Full Text] [Related]
18. Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates. Stein WD; Cardarelli C; Pastan I; Gottesman MM Mol Pharmacol; 1994 Apr; 45(4):763-72. PubMed ID: 7910372 [TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance in a human leukemic cell line selected for resistance to trimetrexate. Arkin H; Ohnuma T; Kamen BA; Holland JF; Vallabhajosula S Cancer Res; 1989 Dec; 49(23):6556-61. PubMed ID: 2573416 [TBL] [Abstract][Full Text] [Related]
20. Modulation of drug resistance in a daunorubicin resistant subline with oligonucleoside methylphosphonates. Vasanthakumar G; Ahmed NK Cancer Commun; 1989; 1(4):225-32. PubMed ID: 2576974 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]